Developmental Cancer Therapeutics Program ABSTRACT The Developmental Cancer Therapeutics (DCT) Program has evolved considerably since 2012 with an increased focus on both solid tumor oncology and the translational aspects of advancing basic science into early-phase clinical trials in rapid fashion. Under the leadership of David Horne, PhD and Edward Newman, PhD, the central theme and overarching goal of DCT are the in-house development of novel, molecularly targeted therapies and drug delivery systems for intractable cancers. Although DCT has continued the Program's long- standing strength in evaluating cancer therapeutics developed through industry partnerships, the emphasis of the DCT Program is to advance important basic discoveries made at the City of Hope Cancer Comprehensive Center (COHCCC). To this end, DCT has established clear scientific goals that fall under three central themes: 1) Support target-directed drug development by identifying and validating new molecular cancer targets/pathways and developing corresponding pharmacological agents; 2) Develop novel drug delivery platforms to improve specificity and efficacy of clinical outcomes; and 3) Translate basic discovery and preclinical studies into early-phase clinical trials. The DCT program extends across eight departments and encompasses a total of 29 Members, of which 12 are basic researchers and 17 are clinicians/clinician scientists. Through the Program, close intra- and inter-programmatic collaborations are fostered among basic scientists and clinical investigators, which in turn has yielded an increase in the number of COH-initiated agents currently under clinical investigation. During the previous grant period, significant infrastructure has been established for the creation of a strong translational research program with greater focus on solid tumor oncology, resulting in a continuous flow of new therapeutic approaches poised for early-phase clinical trials. The emphasis is on speed and precision medicine. With only GLP toxicity studies and some formulation work contracted outside, the DCT Program can rapidly translate discoveries to the clinic. This Program has been further enhanced by the strategic recruitment of key faculty (Chen, Fakih, Fong, Gold, and Salgia), implementation of a drug discovery pipeline, and cGMP manufacturing capability for small molecule drugs, such as COH29, through COH?s in-house Chemical cGMP Synthesis Facility. During the next funding period, we anticipate robust translation of our new therapeutic approaches from the discovery phase to first-in-human clinical trials and continued close collaboration with other regional and national Comprehensive Cancer Centers. Membership: 29 Program Members representing 8 basic and clinical departments Publications: 503 total. 20.1% intra-programmatic; 36.4% inter-programmatic; 41.2% inter-institutional Funding: $4,751,305 peer-reviewed; $1,794,235 of which is NCI funding

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059207
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Tirughana, Revathiswari; Metz, Marianne Z; Li, Zhongqi et al. (2018) GMP Production and Scale-Up of Adherent Neural Stem Cells with a Quantum Cell Expansion System. Mol Ther Methods Clin Dev 10:48-56
Raz, Dan J; Wu, Geena X; Consunji, Martin et al. (2018) The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low-Dose Computed Tomography. Clin Lung Cancer 19:51-57
Solomon, Ilana; Rybak, Christina; Van Tongeren, Lily et al. (2018) Experience Gained from the Development and Execution of a Multidisciplinary Multi-syndrome Hereditary Colon Cancer Family Conference. J Cancer Educ :
Wang, Dongrui; Aguilar, Brenda; Starr, Renate et al. (2018) Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight 3:
Cheng, Chun-Ting; Qi, Yue; Wang, Yi-Chang et al. (2018) Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction. Commun Biol 1:178
Cho, H; Ayers, K; DePills, L et al. (2018) Modelling acute myeloid leukaemia in a continuum of differentiation states. Lett Biomath 5:S69-S98
Querfeld, Christiane; Leung, Samantha; Myskowski, Patricia L et al. (2018) Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6:900-909
Liu, Xuxiang; Cao, Minghui; Palomares, Melanie et al. (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127
Das, Sadhan; Reddy, Marpadga A; Senapati, Parijat et al. (2018) Diabetes Mellitus-Induced Long Noncoding RNA Dnm3os Regulates Macrophage Functions and Inflammation via Nuclear Mechanisms. Arterioscler Thromb Vasc Biol 38:1806-1820
Al Malki, Monzr M; Nathwani, Nitya; Yang, Dongyun et al. (2018) Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1828-1835

Showing the most recent 10 out of 1396 publications